A Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB)
Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This is an open label, risk-stratified, sequential treatment, phase 2 study of newly
diagnosed post-transplant lymphoproliferative disorders with positive CD20 and CD30
expression. It includes an induction phase with rituximab and brentuximab vedotin (RBv),
followed by a treatment phase with RBv or RBv in combination with bendamustine (RBvB) based
on response to induction.
The primary end point is treatment efficacy measured as the overall response rate (ORR) and
progression free survival (PFS).